双功能 TGF-β trap/IL-15 蛋白复合物诱导针对实体瘤的强效 NK 细胞与 CD8⁺ T 细胞免疫

Advances in immunostimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment.

However, novel immunotherapeutics with these dual functions are not frequently reported.

Here we describe the creation of a heterodimeric bifunctional fusion molecule, HCW9218, constructed using our soluble tissue factor (TF)-based scaffold technology. This complex comprises extracellular domains of the human transforming growth factor- (TGF- ) receptor II and a human interleukin-15 (IL-15)/IL-15 receptor complex. HCW9218 can be readily expressed in CHO cells and purified using antibody-based affinity chromatography in a large-scale manufacturing setting. HCW9218 potently activates mouse natural killer (NK) cells and CD8 + T cells in vitro and in vivo to enhance cell proliferation, metabolism, and antitumor cytotoxic activities.

Similarly, human immune cells become activated with increased cytotoxicity following incubation with HCW9218. This fusion complex also exhibits TGF- neutralizing activity in vitro and sequesters plasma TGF- in vivo. In a syngeneic B16F10 melanoma model, HCW9218 displayed strong antitumor activity mediated by NK cells and CD8 + T cells and increased their infiltration into tumors. Repeat-dose subcutaneous administration of HCW9218 was well tolerated by mice, with a half-life sufficient to provide long-lasting biological activity.

Thus, HCW9218 may serve as a novel therapeutic to simultaneously provide immunostimulation and lessen immunosuppression associated with tumors.